Europe Anti-Rheumatic Drug Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Type Of Molecule (Pharmaceuticals, Biopharmaceuticals), By Type (Prescription, Over-the-counter (OTC)), And By Country - Forecasts From 2022 To 2027
- Published : Sep 2022
- Report Code : KSI061613654
- Pages : 85
Europe Antirheumatic Drugs Market is estimated to grow with a CAGR of 2.87% over the forecast period to attain a market size of US$51,553.83 million in 2027, from US$42,299.989 million in 2020.
The antirheumatic drugs market in the European region is expected to grow substantially over the next five years. The major factors that are driving the market growth throughout the region include the moderate incidence of numerous rheumatic diseases in various countries of the region. Furthermore, the presence of the state-of-art pharmaceutical industry in major countries of the European region is also anticipated to be one of the key factors driving market growth throughout the forecast period. The booming investments in pharmaceutical R&D in the region are further widening the opportunities for the market to grow in the coming years. For instance, according to the reports from the European Federation of Pharmaceutical Industries and Association, R&D expenditure in the pharma industry reached €36,500 million in 2018 from €27,920 million in 2010. The pharmaceutical sector is considered one of the most important assets of the European economy. However, the intense outbreak of the deadly coronavirus disease throughout the world has resulted in a shifting focus of the major companies of the region towards the R&D of medicines and drugs to meet the response of the disease is projected to moderately impact the market during the short run.
Furthermore, the market is also poised to grow on account of the increase in the approval of drugs by the authorities for the treatment of rheumatoid arthritis, along with the participation of key players in the form of product launches that further shows the potential for the market to grow in Europe. For example, in December 2019, AbbVie announced that the European Commission approved RINVOQ™ (upadacitinib) for treating moderate to severely active rheumatoid arthritis among adults. Similarly, in February 2017, Eli Lilly and Company and Incyte Corporation were granted authorization for baricitinib — as 2-mg and 4-mg once-daily tablets for treating severe to moderate rheumatoid arthritis, specifically for patients who are intolerant to disease-modifying anti-rheumatic drugs.
The Europe antirheumatic drugs market has been segmented on the basis of the type of disease, type of molecule, and sales channel. On the basis of the type of disease, the market has been classified based on osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By the type of molecule, the market has been segmented into pharmaceuticals and biopharmaceuticals. By the sales channel, the segmentation has been done as prescription and over-the-counter (OTC). On the basis of the country, the segmentation has been done into Germany, France, the UK, Spain, and Others.
COVID has negatively affected the European antirheumatic drugs market. Patients with rheumatoid arthritis who contract COVID-19 infection, according to the Lancet Rheumatology 2020, are at significant risk of developing severe symptoms and consequences. COVID-19 is being studied as a potential therapy with some DMARDs routinely used to treat rheumatoid arthritis, such as hydroxychloroquine medication. Other commonly used medications, such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra), are also being studied in COVID-19 patients. As a result, COVID-19 infection boosted rheumatoid arthritis medicine manufacturers' growth prospects during the anticipated period.
April 2022-The FDA has approved RINVOQ (upadacitinib) as an oral treatment for adults with active ankylosing spondylitis.
- By Type of Disease
- Rheumatoid Arthritis
- By Type of Molecule
- By Type
- Over-the-counter (OTC)
- By Country
1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. Research Methodology
2.1. Research Data
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Function
4.4. Function Value Chain Analysis
5. Europe Anti-rheumatic Drug Market Analysis, By Type of Disease
5.3. Rheumatoid Arthritis
6. Europe Anti-rheumatic Drug Market Analysis, By Type of Molecule
7. Europe Anti-rheumatic Drug Market Analysis, By Type
7.3. Over the Counter (OTC)
8. Europe Anti-rheumatic Drug Market Analysis, By Country
9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. Company Profiles
10.1. AbbVie Inc.
10.2. Pfizer Inc.
10.3. GlaxoSmithKline plc
10.4. Eli Lilly and Company
10.5. Amgen Inc.
10.6. F. Hoffmann-La Roche Ltd
10.7. Johnson & Johnson Services, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Johnson & Johnson Services, Inc.
|Report Name||Published Month||Get Sample PDF|
|Anti-Rheumatic Drug Market Size: Industry Report, 2023–2028||Jun 2023|
|United Kingdom Anti-Rheumatic Drug Market Size: 2022–2027||Jul 2022|
|France Anti-Rheumatic Drug Market Size: Report, 2022–2027||Sep 2022|
|Spain Anti-Rheumatic Drug Market Size: Industry Report, 2023 – 2028||Mar 2023|
|Germany Anti-Rheumatic Drug Market Size: Report, 2022-2027||Sep 2022|